Franklin Templeton Investments related stories
All articles and analysis
Lumira Capital joins G1 Therapeutics' $47 mln Series C roundG1 Therapeutics Inc has raised US$47 million in a Series C financing. The round was led by Cormorant Asset Management with participation from new and existing investors, including Canadian life sciences venture capital firm Lumira Capital. Lumira also invested in the company's Series B round /canada/2015/2/lumira-capital-invests-in-33-mln-series-b-funding-of-g1-therapeutics/ in early 2015. Based in Research Triangle Park, North Carolina, G1 Therapeutics is a developer of novel, small-molecule therapies that help address unmet needs in people with cancer. It plans to use funds raised to advance the clinical development of its lead drug candidate and compound, and grow its pipeline in multiple oncology indications.
GoldPoint Partners moves forward after CIO’s untimely deathSteve Benevento was a “consummate professional” and a “wonderful family man” and it was with great shock that the firm where he served as a senior executive learned of his death, GoldPoint Partners said.
Hays joins Levine LeichtmanRobert Hays has joined Levine Leichtman Capital Partners as an MD and co-head of investor relations. Most recently, Hays was Director of Investor Relations at H.I.G. Capital for five years.
- Defacto Perakende Ticaret sells minority stake to Templeton-led group
Templeton Asset Management Ltd. has led a consortium to buy a minority stake in Defacto Perakende Ticaret A.S. Financial terms weren’t announced. Defactor is an apparel retailer based in Istanbul. Franklin Resources Inc. is the ultimate parent of Templeton Asset Management.
- Natera reels in about $55.5 mln
San Carlos, California-based Natera Inc, a provider of non-invasive genetic testing, has secured about $55.5 million in funding. Sofinnova Ventures led the round with participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors. In conjunction with the funding, Dr James Healy, a general partner at Sofinnova, has been appointed to Natera's board of directors.
On the move, 3.9.15The following hires, promotions and appointments are for the March 9, 2015, issue of Buyouts.
- Darby Private Equity recruits Wallace as marketing and investor relations MD
Darby Private Equity, the private equity arm of Franklin Templeton Investments, has named Michael Wallace as managing director of marketing and investor relations. Prior to joining Darby, Wallace worked at Pinnacle Trust Partners LLC where he served as a managing director.
- Templeton closes Fund IV on $220m
Fund IV has made three investments totaling $59m to date.
- ARX backs Hungarian bottle maker
The deal comes as ARX prepares to come to market with a successor fund.
- ARX Equity Partners and Darby Private Equity acquire Gramex Kft
ARX Equity Partners and Darby Private Equity together with experienced food industry executive Gerard Lenihan have completed the buyout of Gramex 2000 Kft. Financial details of the transaction were not disclosed.